Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Safety and Efficacy Study of VI-0106 (Extended-release Tacrolimus) in Subjects With PAH and Functional Limitations Despite Optimized Treatment With Available PAH Medications

NCT07612657 is registered in ClinicalTrials.gov with VIVUS LLC as lead sponsor.

NCT NCT07612657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07612657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Safety and Efficacy Study of VI-0106 (Extended-release Tacrolimus) in Subjects With PAH and Functional Limitations Despite Optimized Treatment With Available PAH Medications
Lead sponsor
VIVUS LLC
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 29, 2026
Completion date
November 30, 2029
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension, pulmonary arterial hypertension (pah), pulmonary arterial hypertension (pah) (who group 1 ph), pulmonary arterial hypertension pah, pulmonary arterial hypertension who group i